A Phase I Study of Vorinostat in Combination with Bortezomib in Patients with Advanced Malignancies

BACKGROUND: A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors. METHODS: Patients received vorinostat orally once daily on days 1–14...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Schelman, William R., Traynor, Anne M., Holen, Kyle D., Kolesar, Jill M., Attia, Steven, Hoang, Tien, Eickhoff, Jens, Jiang, Zhisheng, Alberti, Dona, Marnocha, Rebecca, Reid, Joel M., Ames, Matthew M., McGovern, Renee M., Espinoza-Delgado, Igor, Wright, John J., Wilding, George, Bailey, Howard H.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901262/
https://ncbi.nlm.nih.gov/pubmed/24114121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0029-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars